Send us an emailKyowa Hakko
COMPANY DETAILS
Am Wehrhahn 50
Düsseldorf
40211
Germany
+49 211 175 450
HEALTH CATEGORIES
Kyowa Hakko is an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals, and food products. Drawing on its expertise in biotechnology and fermentation, Kyowa produces award-winning branded ingredients such as Cognizin® Citicoline, postbiotics IMMUSE® and EYEMUSE®, Setria® Glutathione and has a strong emphasis on research, science, and innovation.
Products / Markets
Our ingredients bear the Kyowa Quality mark, which means that all products are manufactured to meet highest quality assurance standards, supplying quality and trusted materials for various industries such as pharmaceuticals, foods, and cosmetics.
Key branded ingredients include:
IMMUSE®Lactococcus lactis strain Plasma
IMMUSE® is the first lactic acid bacteria that has been clinically researched to directly activate pDCs, a rare subset of immune cells, to provide comprehensive innate and adaptive immune support. It is a well-studied ingredient supported by 30 published studies, 15 human trials and 13 clinical efficacy studies.
Cognizin® Citicoline
Cognizin® Citicoline is a proprietary brain-health nutrient that has been clinically shown to support mental energy, focus, attention and recall. Cognizin® is approved as Novel Food Ingredient in the European Union and can be added to food supplements and food for special medical purposes.
EYEMUSE®Lacticaseibacillus paracasei
EYEMUSE® is a heat-treated probiotic (postbiotic) ofLacticaseibacillus paracasei KW3110 that has shown to combat visual fatigue and promote optimal eye health.
Setria® Glutathione
Known as ‘The Master Antioxidant’, Setria® Glutathione is a tripeptide composed of L-Glutamic acid, L-Cysteine and Glycine. Setria® helps protect cells from the damaging effects of toxins and oxidative stress and plays a key role in supporting immune function.
Setria® Performance Blend
Setria® Performance Blend is a clinically researched blend of glutathione and made in the USA L-Citrulline that may support nitric oxide production. New research in resistance-trained males suggests that Setria® Performance Blend may help sustain NO levels which could lead to reduced fatigue and speed post-workout recovery.
VELOX™ Patented Performance Blend
VELOX™ Blend is a clinically studied blend of two made in the USA amino acids—L-Citrulline and L-Arginine— that has been shown to boost Nitric Oxide levels more rapidly than L-Arginine alone. Help your customers achieve their personal best with VELOX™ Patented Performance Blend .
NUTRITION & HEALTH NEWS
02 Sep 2024 --- In August’s major health and nutrition industry news, the European Food Safety Authority (EFSA) published guidelines on the regulation and use of dietary supplements and we... Read More
NUTRITION & HEALTH NEWS
14 Aug 2024 --- The rigors of a fast-paced modern lifestyle have sparked an uptick of interest in nutrition-based solutions to improve brain health. We caught up with an expert at Kyowa Hakko USA... Read More
REGULATORY NEWS
08 Aug 2024 --- Kyowa Hakko Bio’s 2’-Fucosyllactose (2’-FL) human milk oligosaccharide (HMO) receives approval as a novel food ingredient by the EU’s European Commission... Read More
BUSINESS NEWS
02 Aug 2024 --- This week in nutrition news, the Center for Science in the Public Interest (CSPI) issued a statement in support of the proposed Dietary Supplement Listing Act of 2024, Gencor touted... Read More
NUTRITION & HEALTH NEWS
31 Jul 2024 --- In July’s major health and nutrition industry news, Nutiani published its latest report on “Proactive Nutrition for Healthy Aging,” Bioiberica told us about the... Read More
09 Aug 2024 --- Kyowa Hakko USA has achieved recent advancements in its flagship branded ingredients, Cognizin and Immuse, through cutting-edge research and product development. At IFT First 2024 in Chicago, US, Karen Todd, VP for global brand marketing, explored the consumer trends inspiring this innovation and how the company is looking to expand and strengthen its claims.
19 Jan 2024 --- At FiE 2023, in Frankfurt, Germany, we sat down with Keiji Iga, the senior manager and head of business development Europe at Kyowa Hakko, to discuss its venture in human milk oligosaccharides (HMOs) production. He details the health benefits and versatility of 6’-Sialyllactose sodium salt and gives insights into the results of Kyowa Hakko’s recent novel food applications for 2’-Fucosyllactose and 3’-Sialyllactose sodium salt. We also explore the company’s plans for 2024.
26 Jan 2021 --- In light of the increasing global demand for HMOs, Kyowa Hakko Bio is eyeing opportunities within the Chinese and Thai markets, despite a hazy regulatory environment. Moreover, the company is investing in a new Thai facility to expand its production capacity. Kentaro Yanashima, Research & Business Development for Kyowa Hakko Bio, tells NutritionInsight all about the promising potential of HMO’s for both infant and adult nutrition and the company’s expansion plans.
17 Oct 2022 --- IMMUSE® Lactococcus lactis strain Plasma is a unique, patent-protected, heat-killed lactic acid bacteria strain, more commonly referred to as a postbiotic, with a novel mechanism of action that stimulates immune function at the cellular level.This Technical Paper is from Kyowa Hakko.
26 Jul 2021 --- This week’s NewsBite podcast details how COVID-19 has had a major impact on consumer habits around supplementation, with NPD tackling everything from weight management to immunity. Additionally, Kappa Bioscience investigated the link between COVID-19 outcomes and levels of vitamins D and K2.
